CMAB Biopharma, a Chinese contract development and manufacturing organization based in Suzhou, teamed up with QureBio to develop Q-1802.
The bispecific antibody is now ready for an investigational new drug (IND) application with the US and China, after nine months of development by CMAB.
The CDMO carried out all of the development work in-house, utilizing its integrated platform. As part of the process, CMAB created three 200L batches using single-use bioreactors, with the last batch expected to be fully released in two months.
QureBio is Chinese biotech based in Shanghai that was established in 2017. Earlier this year, the biotech secured ￥10M ($1.4m) in a financing round to develop two preclinical projects, Q-1802 and Q-1801.
QureBio’s Q-1802 is a bispecific antibody that is being tested as a treatment of solid tumors, such as gastric cancer. In China, gastric cancer is one of the leading causes of death. While Q-1801 targets the tumor microenvironment.
Yejie Du, QureBio’s head of CMC, noted that the two companies would work together to pursue dual IND filings in China and the US, as well as to take its ‘major products’ into clinical trials.
